Form 4: Hologic Director Ludwig Hantson Reports Acquisition of Stock and Stock Options

Director Ludwig Hantson reports acquisition of common stock and stock options in Hologic Inc.

Summary

• On March 7, 2024, Ludwig Hantson, a director of Hologic Inc., reported the acquisition of 1,572 shares of common stock.
• These shares were acquired as restricted stock units that vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock.
• Hantson also acquired 4,536 non-qualified stock options with an exercise price of $76.32, which become exercisable on the date of the 2025 Annual Meeting of Stockholders and expire on March 7, 2034.
• Following these transactions, Hantson beneficially owns 11,092 shares of common stock, including 3,695 restricted stock units with deferred settlement, and 4,536 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option acquisitions by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock and stock options by a director may be viewed positively by investors as it aligns the director's interests with those of the shareholders.

Future Outlook

The restricted stock units will vest, and the stock options will become exercisable on the date of the 2025 Annual Meeting of Stockholders.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares and options by a director can signal confidence in the company's future performance, potentially impacting shareholder sentiment positively.

Key Dates